Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.
Latest price
$189.34
+1.56%
Alpha Vantage · 11/9/2026
Adjusted daily closes · 252 observations · as of Nov 9, 2026
1 month
+19.0%
3 months
+19.3%
6 months
+4.8%
1 year
+13.9%
Year to date
+4.8%
52-week range
$154.61 – $207.09
Latest reported period: Sep 30, 2026
Market cap
$293.74B
P/E
26.6
P/B
5.7
P/S
4.7
Revenue
$62.38B
Net income
$11.03B
Diluted EPS
7.06
Gross margin
81.90%
Net margin
17.70%
Return on equity
22.30%
Total debt
$34.19B
Cash
$7.94B
Free cash flow
$10.23B
Reported quarterly values, newest first
| Period | Revenue | Net income | Gross margin | Net margin | Free cash flow |
|---|---|---|---|---|---|
| Sep 30, 2026 | $16.21B | $3.12B | 81.80% | 19.20% | $3.99B |
| Jun 30, 2026 | $15.38B | $2.51B | 83.60% | 16.30% | $2.11B |
| Mar 31, 2026 | $15.29B | $3.08B | 82.50% | 20.10% | $2.82B |
| Dec 31, 2025 | $15.5B | $2.33B | 79.90% | 15.00% | $1.31B |
| Dec 31, 2025 | $15.5B | $2.33B | 79.90% | 15.00% | $1.31B |
| Sep 30, 2025 | $15.19B | $2.53B | 81.60% | 16.70% | $4.45B |
| Jun 30, 2025 | $14.46B | $2.45B | 82.90% | 16.90% | $2.74B |
| Mar 31, 2025 | $13.59B | $2.92B | 83.50% | 21.50% | $3.29B |
Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.
AstraZeneca PLC has notified a change in its major holdings in NIOX Group PLC, crossing a threshold on October 22, 2026. This change resulted from an acquisition or disposal of voting rights and a change in the Issuer's total voting rights following a tender offer. AstraZeneca PLC now holds 16.31% of the voting rights in NIOX Group PLC, amounting to 66,093,108 shares.
Original source